Form 4: Werewolf Therapeutics Director Sells $290K in Stock

Ansbert Gadicke and affiliated entities divested over 240,000 shares of Werewolf Therapeutics common stock in early November 2025 under a Rule 10b5-1 trading plan.

Summary

• Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), along with several affiliated entities, reported sales of common stock.
• A total of 242,890 shares were sold across three separate transactions on November 4, 5, and 6, 2025.
• The sales were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• The weighted average sale prices for these transactions ranged from $1.21 to $1.22 per share.
• Following these sales, the total indirect beneficial ownership by the reporting persons decreased to 5,904,720 shares.
• The shares were sold by various entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Sentiment

Score: 3

Explanation: Significant insider selling by a director and major shareholder, even under a pre-arranged plan, can be perceived negatively by the market as it reduces insider alignment and may signal a belief that the stock is fully valued or overvalued.

Negatives

• Significant insider selling by a Director and 10% owner, which can be perceived negatively by the market.
• The sales occurred at relatively low prices, with weighted averages between $1.21 and $1.22 per share, and individual transactions ranging from $1.17 to $1.30.

Risks

• Potential negative market perception due to substantial insider selling, which could lead to downward pressure on the stock price.
• Reduced insider ownership might signal a lack of confidence in the company's future prospects, even if the sales were pre-planned under a 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports insider trading activity, which is specific to the company and its insiders, rather than reflecting broader industry trends. However, significant insider selling in the biotechnology sector can sometimes be viewed with caution by investors.

Related Party Transactions

• Sales of common stock by MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P., all of which are affiliated with Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price or a reassessment of the company's valuation.

Key Dates

Recommendation

The significant insider selling by a director and 10% owner, Ansbert Gadicke, and his affiliated entities, even if pre-planned, suggests that these key stakeholders are reducing their exposure to Werewolf Therapeutics. This action, especially at the reported price range, could indicate a belief that the stock's near-term upside is limited or that current valuations are fair to high. For a seasoned investor, this often signals a prudent time to consider reducing or exiting positions, as insider selling can precede periods of underperformance.

Keywords

Werewolf Therapeutics, HOWL, Insider Trading, Form 4, Stock Sale, Ansbert Gadicke, MPM BioImpact, 10b5-1 plan, beneficial ownership